Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 36

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---

The Company has a single segment and allocates resources based on cash resources and operating expense projections. The table below summarizes the significant expense categories regularly reviewed by the Company’s president and chief executive officer, who is the Company’s chief operating decision maker (“CODM”), for the three and nine months ended September 30, 2025 and 2024:Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Research and development expenses:Clinical trial expenses:IT-01 Study (Phase 1/2 Metastatic Cancers) (a)$— $53 $— $114 INVINCIBLE-2 Study (Phase 2 Breast) (a)— 12 — 233 INVINCIBLE-3 Study (Phase 3 Sarcoma) (b)883 1,225 3,267 4,613 INVINCIBLE-4 Study (Phase 2 Breast) (c)126 108 323 424 Other clinical trial expenses— — 14 58 Clinical trial expenses1,009 1,398 3,604 5,442 Contract manufacturing30 20 59 651 Salaries and benefits related303 497 925 1,340 Consulting & Other (d)29 49 90 126 Stock-based compensation182 187 605 970 Research and development expenses1,553 2,151 5,283 8,529 General and administrative expenses:Salaries and benefits related225 325 688 949 Legal fees130 113 371 545 Audit fees72 113 237 286 Consulting145 234 461 573 Insurance185 157 501 718 Other (e)134 181 347 523 Stock-based compensation289 296 944 1,259 General and administrative expenses1,180 1,419 3,549 4,853 Loss from operations(2,733)(3,570)(8,832)(13,382)Other segment items (f)62 57 277 295 Net loss$(2,671)$(3,513)$(8,555)$(13,087)*Completed study(a)Completed study.(b)In March 2025, the Company paused new site activations and patient enrollments due to funding constraints.(c)In September 2025, the Company paused new patient enrollment to